Table of Contents Author Guidelines Submit a Manuscript
International Journal of Inflammation
Volume 2011, Article ID 727634, 9 pages
http://dx.doi.org/10.4061/2011/727634
Research Article

Modelling Cost-Effectiveness of Biologic Treatments Based on Disease Activity Scores for the Management of Rheumatoid Arthritis in Spain

1R&D, Data Mining International, 1215 Geneva, Switzerland
2LIRAES, Paris Descartes University, 75270 Paris cedex 06, France
3Rheumatology, Hospital Universitario Virgen Macarena, 41007 Sevilla, Spain
4Rheumatology, Hospital de Basurto, 48013 Bilbao, Spain
5Pharmacoeconomics Department, Bristol-Myers Squibb, Iberia, 28040 Madrid, Spain
6Health Economics and Outcomes Strategy, Bristol-Myers Squibb Europe, 1420 Braine-l'Alleud, Belgium

Received 14 February 2011; Accepted 2 May 2011

Academic Editor: B. L. Slomiany

Copyright © 2011 Ariel Beresniak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Brighton, A. de la Harpe, D. van Staden, J. Badenhorst, and O. Myers, “The prevalence of rheumatoid arthritis in a rural African population,” Journal of Rheumatology, vol. 15, no. 3, pp. 405–408, 1988. View at Google Scholar · View at Scopus
  2. M. Cimmino, M. Parisi, G. Moggiana, G. Mela, and S. Accardo, “Prevalence of rheumatoid arthritis in Italy: the Chiavari study,” Annals of the Rheumatic Diseases, vol. 57, no. 5, pp. 315–318, 1998. View at Google Scholar · View at Scopus
  3. M. Simonsson, S. Bergman, L. T. H. Jacobsson, I. F. Petersson, and B. Svensson, “The prevalence of rheumatoid arthritis in Sweden,” Scandinavian Journal of Rheumatology, vol. 28, no. 6, pp. 340–343, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Guillemin, S. Durieux, J. P. Daures et al., “Costs of rheumatoid arthritis in France: a multicenter study of 1109 patients managed by hospital-based rheumatologists,” Journal of Rheumatology, vol. 31, no. 7, pp. 1297–1304, 2004. View at Google Scholar · View at Scopus
  5. L. Carmona, V. Villaverde, C. Hernández-García, J. Ballina, R. Gabriel, and A. Laffon, “The prevalence of rheumatoid arthritis in the general population of Spain,” Rheumatology, vol. 41, no. 1, pp. 88–95, 2002. View at Google Scholar · View at Scopus
  6. J. Carbonell, T. Cobo, A. Balsa, M. Descalzo, L. Carmona, and SERAP Study Group, “The incidence of rheumatoid arthritis in Spain: results from a nationwide primary care registry,” Rheumatology, vol. 47, no. 7, pp. 1088–1092, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. E. Loza, L. Abasolo, D. Clemente et al., “Variability in the use of orthopedic surgery in patients with rheumatoid arthritis in Spain,” Journal of Rheumatology, vol. 34, no. 7, pp. 1485–1490, 2007. View at Google Scholar · View at Scopus
  8. L. Carmona, I. González-Alvaro, A. Balsa, M. A. Belmonte, X. Tena, and R. Sanmartí, “Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity,” Annals of the Rheumatic Diseases, vol. 62, no. 9, pp. 897–900, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Redlich, G. Schett, G. Steiner, S. Hayer, E. Wagner, and J. Smolen, “Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade,” Arthritis and Rheumatism, vol. 48, no. 12, pp. 3308–3319, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. K. Hyrich, M. Lunt, K. Watson, D. Symmons, A. Silman, and British Society for Rheumatology Biologics Register, “Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study,” Arthritis and Rheumatism, vol. 56, no. 1, pp. 13–20, 2007. View at Google Scholar
  11. C. Rubio-Terres, J. P. Ordovás Baines, R. Pla Poblador et al., “Use and cost of biological disease -modifying anti-rheumatic drugs in Spain (PRAXIS study),” Farmacia Hospitalaria, vol. 31, no. 2, pp. 78–92, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Russell, A. Beresniak, L. Bessette et al., “Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis,” Clinical Rheumatology, vol. 28, no. 4, pp. 403–412, 2008. View at Google Scholar
  13. A. Saraux, L. Gossec, P. Goupille et al., “Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France,” Rheumatology, vol. 49, pp. 733–740, 2010. View at Google Scholar
  14. M. C. Genovese, J. C. Becker, M. Schiff et al., “Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition,” New England Journal of Medicine, vol. 353, no. 11, pp. 1114–1123, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. M. C. Genovese, M. Schiff, M. Luggen et al., “Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy,” Annals of the Rheumatic Diseases, vol. 67, no. 4, pp. 547–554, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. S. Bombardieri, A. A. Ruiz, P. Fardellone et al., “Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice,” Rheumatology, vol. 46, no. 7, pp. 1191–1199, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. S. Cohen, P. Emery, M. Greenwald et al., “Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks,” Arthritis and Rheumatism, vol. 54, no. 9, pp. 2793–2806, 2006. View at Google Scholar
  18. E. Keystone, R. Fleischmann, P. Emery et al., “Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis,” Arthritis and Rheumatism, vol. 56, no. 12, pp. 3896–3908, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. S. Gabriel, M. Drummond, A. Maetzel et al., “OMERACT 6 Economics Working Group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis,” Journal of Rheumatology, vol. 30, no. 4, pp. 886–890, 2003. View at Google Scholar · View at Scopus
  20. G. Kobelt, P. Lindgren, Y. Lindroth, L. Jacobson, and K. Eberhardt, “Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis,” Rheumatology, vol. 44, no. 9, pp. 1169–1175, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. M. Osiri, P. Kamolratanakul, A. Maetzel, and P. Tugwell, “Cost effectiveness analysis of disease modifying antirheumatic drugs in rheumatoid arthritis,” Rheumatology International, vol. 27, no. 11, pp. 1063–1069, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. G. Kobelt, “Thoughts on health economics in rheumatoid arthritis,” Annals of the Rheumatic Diseases, vol. 66, supplement 3, pp. iii35–iii39, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. M. C. Weinstein, “Recent developments in decision-analytic modelling for economic evaluation,” PharmacoEconomics, vol. 24, no. 11, pp. 1043–1053, 2006. View at Google Scholar · View at Scopus
  24. A. Beresniak, A. S. Russell, B. Haraoui, L. Bessette, C. Bombardier, and G. Duru, “Advantages and limitations of utility assessment methods in rheumatoid arthritis,” Journal of Rheumatology, vol. 34, no. 11, pp. 2193–2200, 2007. View at Google Scholar · View at Scopus
  25. A. Kielhorn, D. Porter, A. Diamantopoulos, and G. Lewis, “Uk cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug,” Current Medical Research and Opinion, vol. 24, no. 9, pp. 2639–2650, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. M. Vera-Llonch, E. Massarotti, F. Wolfe et al., “Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-α antagonists,” Journal of Rheumatology, vol. 35, no. 9, pp. 1745–1753, 2008. View at Google Scholar · View at Scopus
  27. A. J. Wailoo, N. Bansback, A. Brennan, K. Michaud, R. M. Nixon, and F. Wolfe, “Biologic drugs for rheumatoid arthritis in the medicare program: a cost-effectiveness analysis,” Arthritis and Rheumatism, vol. 58, no. 4, pp. 939–946, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. G. Duru, J. P. Auray, A. Beresniak, M. Lamure, A. Paine, and N. Nicoloyannis, “Limitations of the methods used for calculating quality-adjusted life-year values,” PharmacoEconomics, vol. 20, no. 7, pp. 463–473, 2002. View at Google Scholar · View at Scopus
  29. M. McGregor and J. J. Caro, “QALYs: are they helpful to decision makers?” PharmacoEconomics, vol. 24, no. 10, pp. 947–952, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Ariza-Ariza, B. Hernández-Cruz, L. Carmona et al., “Assessing utility values in rheumatoid arthritis: a comparison between time trade-off and the EuroQol,” Arthritis and Rheumatism, vol. 55, no. 5, pp. 751–756, 2006. View at Google Scholar
  31. C. A. Marra, J. C. Woolcott, J. A. Kopec et al., “A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis,” Social Science and Medicine, vol. 60, no. 7, pp. 1571–1582, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. B. Conner-Spady and M. E. Suarez-Almazor, “Variation in the estimation of quality-adjusted life-years by different preference-based instruments,” Medical Care, vol. 41, no. 7, pp. 791–801, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. P. M. Welsing, H. L. Swinkels, L. A. Keimeney, and P. L. van Riel, “The relationship between disease activity, joint destruction and functional capacity over the course of rheumatoid arthritis,” Arthritis and Rheumatism, vol. 44, no. 9, pp. 2009–2017, 2001. View at Google Scholar